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Background. Oral intake of many patients with locally advanced head and neck cancer (LAHNC) decrease during chemoradio-
therapy (CRT). Although prophylactic percutaneous endoscopic gastrostomy (PEG) is recommended, not a few patients complete
CRTwithoutusingPEGtube.PatientsandMethods.ThesubjectswerepatientswithLAHNCwhoreceivedCRT.Weretrospectively
investigated the incidence and duration of nutritional support during and after CRT, and predicting factors of nutritional support.
For patients who required nutritional support, we also checked the day of initiation and the duration of nutritional support.
Results. Of 53 patients, 29 patients (55%) required nutritional support during and/or after CRT. While no clear relation between
requirement of nutritional support and variables including age, T stage, N stage, clinical stage and chemotherapy regimen, there
could be some relationships between tumor primary sites and the requirement and duration of nutritional support. 17 (77%) of
22 patients with oropharynx cancer(OP) required nutritional support and prolonged for 4.4 months, and 11 (46%) of 24 patients
with hypopharynx cancer(HP) required nutritional support and prolonged for 21.9 months. Conclusion. Nutritional support is
indicated many HNC patients treated with CRT and primary sites may have some relation to its indication and duration.
1.Introduction
Chemoradiotherapy (CRT) is one of the treatment choices
for locally advanced head and neck squamous cell carcinoma
(HNCSCC), not only for patients with unresectable disease,
but also for those who desire organ preservation. However,
the treatment course is often complicated by the develop-
ment of painful mucositis, which causes diﬃculty in oral
intake. Furthermore, in some patients, dysphagia occurring
as a result of CRT causes life-threatening aspiration pneu-
monia during and/or after treatment [1, 2]. These obstacles
to oral intake often result in treatment failure, prolongation
of hospitalization, and treatment-related death [3]. Many
physicians have begun to pay more attention to these adverse
eﬀects and to developing means to overcome these adverse
eﬀects and support the patients’ nutrition during and after
CRT [4]. While placement of a percutaneous endoscopic
gastrostomy (PEG) or gastric feeding tube (GFT) before
CRT is recommended in Western countries, prophylactic
placementofaGFThasgenerallynotbeenacceptedinJapan.
Inaddition,somepatientsdonotrequirenutritionalsupport
at all. It would be reasonable to carefully select patients in
whom PEG or GFT should be considered prior to CRT.
There are only few reports concerning nutritional sup-
port for HNSCC patients treated by CRT [5]. Especially,
there have been no reports about the relationship between
the indications and duration of nutritional support and
the clinical backgrounds of HNSCC patients. This is the2 ISRN Oncology
Table 1
n = 53
Age Median (range) 62 (45–77)
Gender Male/female 49/4
Primary sites OP/HP/L 22/24/7
T 1/2/3/4 2/18/12/21
N 0/1/2a/2b/2c/3 6/3/2/9/25/8
Stage II/III/IV 4/3/46
Chemotherapy regimen
CDDP+ 5-FU+RT 30
CDDP+ RT 17
Nedaplatin +5-FU+RT 3
Carboplatin + RT 3
RT dose Median (range) 70 (60–70)
Abbreviations; OP: Oropharynx, HP: Hypopharynx, and L: Larynx.
ﬁrst report on the incidence and duration of nutritional
support during and after CRT in patients with HNSCC and
of determination of the indication for nutritional support
according to the clinical backgrounds of the patients.
2.SubjectsandMethods
2.1. Subjects. Patients with HNSCC receiving CRT as the
ﬁrst-line therapy at Shizuoka Cancer Center between 2002
and 2006, who fulﬁlled the following criteria were enrolled
as the subjects of this retrospective study; (1) primary site,
oropharynx (OP), hypopharynx (HP), or larynx (L); (2) no
other malignancy; (3) completed CRT; (4) adequate oral
intake before CRT. The clinical stage of the disease was clas-
siﬁed according to the UICC TNM classiﬁcation.
2.2. Treatment. All patients received concomitant CRT. The
total radiation dose was 60–70Gy, administered in 30–35
conventional fractions. The chemotherapy regimens were
selected from the following four regimens, in accordance
with the physicians’ judgment of the patient’s medical
condition and the availability of informed consent from the
patient; (1) 5-ﬂuorouracil (5-FU, 400mg/m2, ci, days 1–5,
days 36–40) plus cisplatin (CDDP, 80mg/m2,d i vd a y s1
and 36), (2) CDDP alone (100mg/m2, div, days 1, 22, 43),
(3) nedaplatin (90mg/m2, div, days 1 and 36) and 5-FU
(400mg/m2, ci, days 1–5, days 36–40), and (4) carboplatin
alone (AUC = 5, days 1 and 29). Treatment response was
assessed according to the RECIST.
2.3. Evaluation of Nutritional Support. The time to provision
of nutritional support was calculated from the date of start
of the CRT to the date of start of nutritional support.
The duration of nutritional support was calculated as the
total number of days for which the patients received enteral
nutrition (EN) via a feeding tube (nasogastric feeding tube;
NGFT or GFT) or total parental nutrition (TPN), because
of the lack of ability for adequate oral intake, regardless of
the amount of oral intake and calories provided through
nutritional support; the days on which the patients received
no calories through NGFT/GFT/TPN were not included
Table 2
CR non CR Total
OP 11 11 22
HP 13 11 24
L4 3 7
Total 28 25 53
Abbreviations; CR: complete response.
in the calculation of the duration of nutritional support,
regardless of the presence of a PEG, GFT, or central venous
catheter in place. The nutritional support-free survival was
calculated by subtracting the duration of nutritional support
from the overall survival, and the patients were censored
whentheyreceivedsurgeryforresidualtumororlocalrelapse
or died.
2.4. Statistics. The relationship between the clinical back-
groundcharacteristicsandindicationfornutritionalsupport
was analyzed by the chi-square test. Then, the durations
of nutritional support-free survival and nutritional support
were analyzed by the Kaplan-Meier method and log-rank
test.
3. Results
3.1. Patient Background. A total of 74 patients with HNSCC
received CRT as the ﬁrst-line therapy at our center during
the study period. Fourteen patients having double cancer,
six patients with insuﬃcient oral intake, and one patient in
whom the CRT was not completed were excluded, and the
remaining 53 patients were enrolled as the subjects of this
study.
The patient characteristics are shown in Table 1.T h e
median age was 62 years, and there were 49 male and 4
female patients. The primary sites were the OP, HP, and L in
22, 24, and seven patients, respectively. Most had advanced
disease; T stage 1/2/3/4 in 2/18/12/21 patients, N stage
0/1/2a/N2b/2c/3 in 6/3/2/9/25/8 patients, and clinical stage
II/III//IV in 4/3/46 patients.
3.2. Treatment. Thirty patients received CDDP and 5-FU, 17
patientsreceivedCDDPalone,threereceivednedaplatinplus
5-FU, and three patients received carboplatin alone. The best
overall responses are shown in Table 2. Complete response
(CR) was achieved in 28 patients (53%). Stratiﬁed according
to the primary site, CR was obtained in 11 patients (50%)
with primary cancer of the OP, in 13 patients (54%) with
the cancer arising from the HP, and 4 (57%) with a primary
tumor of the L. The mean survival times were 623 days for
patients with tumors of the OP, 1111 days for patients with
tumors arising from the HP, and 1408 days for patients with
primary tumor of the L.
3.3. Nutritional Support. In this study, the nutritional
support-free survival rates at two months from the start of
the CRT were 27% for patients with tumors arising fromISRN Oncology 3
Table 3
Nutrition supported Not supported P value
n = 24 (45%) n = 29 (55%)
Male/female 24/0 25/4 0.21
Age (range) 60 (45–77) 60 (47–74) 0.48
∗
OP/HP/L 5/13/6 17/11/1 0.02∗∗
T1,2,3/4 16/8 16/13 0.51
N0,1,2a/2b,2c,3 8/16 4/25 0.2
Stage II, III/IV 5/19 2/27 0.15
Chemotherapy regimen (including 5-FU/without 5-FU) 17/13 16/7 0.33
Resectability (yes/no) 10/19 11/13 0.4
∗Over 70 versus under 69.
∗∗OP versus HP.
the OP and 64% for patients with tumors arising from the
HP. Finally, 77% of the patients with primary tumor of the
OP and 46% of the patients with tumor arising from the
HP required nutritional support throughout the duration of
the CRT (Figure 1). Table 3 shows the relationship between
the clinical background characteristics and the need for
nutritional support. In total, 29 patients (55%) required
nutritional support. The need for nutritional support was
more frequent in patients with tumor arising from the
HP than in those with primary tumor of the OP (P =
0.02). There were no signiﬁcant diﬀerences in the other
variables,includingtheage,distributionofgender,Tstage,N
stage, clinical stage or chemotherapy regimens, or the tumor
resectability among the groups. A signiﬁcant diﬀerence in
the nutritional support-free survival was observed between
patientswithtumorsarisingfromtheOPandHP(P = 0.01).
The nutritional support-free survival rates at one month
were 50% and 84%, and those at two months were 27% and
64%, in the patients with tumors arising from the OP and
HP, respectively. Finally, 23% of the patients with primary
tumoroftheOPand54%ofthepatientswithprimarytumor
oftheHPdidnotrequirenutritionalsupportthroughoutthe
duration of the CRT.
Figure 2 shows the duration of nutritional support
according to the primary site of the tumors. The median
duration of nutritional support was 133 days in the patients
with primary tumor of the OP and 657 days in those with
primary tumor of the HP; 10% of patients with primary
tumor of the OP and 71% of patients with primary tumor
of the HP required nutritional support for more than one
year (P = 0.002).
4. Discussion
In recent years, CRT has come to be recognized as an
important treatment modality for locally advanced HNSCC.
Especially patients with unresectable disease and those who
do not wish to lose their voice by surgery, CRT is the
treatment modality with curative intent of ﬁrst choice.
However, CRT is associated with severe toxicities, such as
grade 3 or 4 mucositis, and the associated pain and/or
burning sensation make oral intake diﬃcult. Placement
of a nutritional support device before CRT is generally
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Figure 1
recommended to improve the feasibility of CRT. Actually,
77% of the patients with primary tumor arising from the OP
and 46% of patients with primary tumor arising from the
HP required nutritional support throughout the duration of
CRT in this study.
Placement of a nutritional support device before CRT
is generally recommended to improve the feasibility and
likelihood of completion of CRT [6, 7]. However, in quite
a few patients, CRT can be completed without provision of
any nutritional support. For such patients, placement of a
nutritional support device might represent overtreatment.
Thus, it is important to identify which patients might actu-
ally require nutritional support. In this study, the nutrition
support-free survival rates were 27% in the patients with
primary tumor of the OP and 64% in those with primary
tumor of the HP at two months from the beginning of the
CRT; furthermore, 23% of the patients with primary tumor
of the OP and 54% of the patients with primary tumor
of the HP did not require nutritional support at all. These4 ISRN Oncology
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ﬁndings suggest that approximately more than half of the
patients with primary tumor arising from the HP did not
require nutritional support, while about three quarters of all
patients with primary tumor arising from the OP needed
nutritional support. Our ﬁndings suggest that the site of
origin of the primary tumor may be a predictor of the need
for nutritional support, while none of the other clinical
backgroundcharacteristicsappearedtoberelatedtotheneed
for nutrition support.
Even after completion of CRT and resolution of the
mucositis, some patients suﬀer from prolonged persistent
dysphagia and continue to need nutritional support via tube
feeding or TPN, until they recover their ability to swallow
ability recovers [8, 9]. In this study, the median duration of
nutritionalsupportwas133daysinthepatientswithprimary
tumor of the OP and 657 days in patients with primary
tumor of the HP. Furthermore, 10% of the patients with
primary tumor arising from the OP and 71% of the patients
withprimarytumorarisingfromtheHPrequirednutritional
support for more than one year. While CRT may be a useful
modality for preserving the organ and voice, unfortunately,
it may impair the ability for adequate oral intake. Because
we did not evaluate the swallowing ability by a barium test
before and after the CRT, it is not known precisely why and
how the patients complained of diﬃculty in oral intake. It
is speculated that swallowing dysfunction or mental stress
may be the reason for the inadequate oral intake, since the
organs for swallowing are mechanically preserved [10–12].
The usefulness of additional approaches, such as precise
evaluation of the swallowing ability and provision of practice
for swallowing throughout the course of the CRT should be
investigated to prevent dysphagia.
Furthermore, approximately 30% of patients with pri-
mary tumor arising from the HP patients required nutri-
tional support even after the completion of CRT. Once the
patients were started on nutritional support, it took 4.4
months for patients with primary tumor arising from the
OP and 21.9 months for those with the primary tumor
arising from the HP before the patients could eat well
enough and the nutritional support could be discontinued.
While most patients with primary tumor arising from the
oropharynx required nutritional support, the duration of
nutritional support was rather short, and only a half of
the patients required prolonged nutritional support. It is
speculated that mucositis and edema of the oral mucosa,
tongue, and pharynx in the patients with primary tumor
of the OP during CRT, which make oral intake diﬃcult,
resolve soon after CRT without residual dysfunction. On
the contrary, patients with primary tumors arising from
the HP, damage to the important structures for swallowing,
such as the pharyngeal stricture muscles, might be present,
or stricture of the pharynx to cervical esophagus might be
inﬂicted by the CRT, increasing the time until recovery of the
swallowing functions [13]. Thus, it is suggested that diﬀerent
strategies for nutritional support, taking into consideration
the primary tumor site, should be considered.
5. Conclusion
Nutritional support for HNSCC patients receiving CRT
is very important. The optimal strategy for provision of
nutritional support according to the primary site of the
tumor should be investigated for preservation of normal
swallowing function.
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